comparemela.com

Latest Breaking News On - Evolving treatment paradigms - Page 5 : comparemela.com

Circulating Tumor DNA as a Prognostic Marker in HR+/HER2- Breast Cancer

A discussion on the use of circulating tumor DNA (ctDNA) as a prognostic biomarker in HR+/HER2- breast cancer.

Evolving treatment paradigmsRecent data updatesPrognostic markerHr her2 breast cancerCdk4 6 inhibitorsPenelope bBiomarker testing

Initiating Treatment for Lower-Risk MDS With Symptomatic Anemia

The panel shares at what point they decide to start treatment for patients with lower-risk MDS and symptomatic anemia.

Myelodysplastic syndromesRecent updatesEvolving treatment paradigms

First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

Yazan Madanat, MD, details the available options for first-line treatment of patients with lower-risk MDS and symptomatic anemia.

Yazan madanatMyelodysplastic syndromesRecent updatesEvolving treatment paradigmsLine treatment options

COMING SOON: Recent Updates in Hepatocellular Carcinoma (HCC) and Evolving Treatment Paradigms

Rachna Shroff, MD, provides a look at an upcoming program reviewing recent data updates in the treatment of hepatocellular carcinoma.

Rachna shroffHepatocellular carcinomaRecent updatesEvolving treatment paradigmsEvolving treatment

Risk Stratification of MDS

Amer Zeidan, MBBS, MHS, explains risk stratification in MDS, how the process has evolved over time, and the guidelines he typically follows.

Samer zeidanMyelodysplastic syndromesRecent updatesEvolving treatment paradigmsMyelodysplastic syndromes recent updatesTreatment evolution myelodysplastic syndromesMds managementAsco 20232023 asco annual meetingAmerican society of clinical oncologyMds symptomsMds diagnosisMds presentationsHigh risk mdsLow risk mds

vimarsana © 2020. All Rights Reserved.